Search

Abstract Background The aim of this study was to determine the prevalence of Dal, and DEA 1, 4, 7 blood types, in a population of canine blood donors from Italy and Spain. Three hundred and twenty blood donor dogs receiving an annual health evaluation were included in the study. DEA 1 blood type was determined using an immunochromatographic strip technique while Dal, DEA 4 and 7 blood types were determined with polyclonal antisera using agglutination on gel columns. Results Out of 320 dogs blood typed 7 (2 Cane Corso and 5 Doberman Pinschers) (2.2%) were Dal negative; 137 (42.8%) were positive for DEA 1; 320 (100%) were positive for DEA 4 and 43 (13.4%) were positive for DEA 7. Conclusion This study showed a similar prevalence of DEA 1, 7 and 4 to that reported in previous studies in the same, and in different, geographic areas, and provides new data on the prevalence of the Dal blood group in Italy and Spain. There was no significant difference (P = 0.8409) between prevalence of Dal negative blood types found in our population (2.2%) and the prevalence reported in a canine blood donor population from the USA (2.5%). Our study identified Dal negative dogs in a previously tested breed i.e. Doberman Pinschers, but also the Cane Corso breed was found to have Dal negative dogs.

The erythrocyte sedimentation rate (ESR) in canine medicine has been replaced by the evaluation of a few sensitive markers of the acute-phase proteins. The aim of the study was to evaluate the ESR using a point-of-care (MINIPET, DIESSE Diagnostica Senese S.p.A.) device (ESR-MP) and to compare the results with the gold standard Westergren method (ESR-W) in dogs. One hundred and nineteen K3-EDTA blood samples for complete blood count were randomly selected and assayed for ESR. The reference interval (RI) was established using the percentile method. The coefficient of variation (CV) in intra-assay and interassay precision of ESR-MP was calculated. The analytical sensitivity (Se), specificity (Sp), positive predictive values (PPVs), and negative predictive values (NPVs) were calculated. Agreement between ESR-MP and ESR-W was assessed with Pearson correlation coefficient (r), Cohen concordance test (K), Passing-Bablok regression, and Bland–Altman plots. Ten canine samples (8.4%) were ruled out because of flag-error by the MINIPET instrument (4.2%) or because they showed the diphasic pattern in ESR-W (4.2%). The canine RI of ESR-MP was 0–10 mm/h. Precision was excellent in intra-assay (CV = 0.02) and interassay (CV = 0.32). The analytical characteristics of ESR-MP in nonanemic samples were as follows: Se = 0.82, Sp = 0.95, PPV = 0.82, and NPV = 0.95. The accuracy of ESR-MP was better than ESR-W in nonanemic samples (r = 0.87; K = 0.77) and lower in anemic subjects (Hct

The vaccine Canileish® is distributed in Europe to reduce the risk of developing an active infection and clinical leishmaniosis. An English Setter dog vaccinated with Canileish® and treated with anti-feeding and repellent medications showed typical clinical signs of leishmaniosis. The dog was presented with dysorexia, weight loss, fever and forelimb lameness. The physical exam revealed moderate generalized external lymph node enlargement, sero-purulent ocular discharge, photophobia, and swollen and painful right carpal joint. Clinico-pathological findings revealed moderate microcytic-hypochromic non-regenerative anemia, mild neutropenia and thrombocytopenia, hyperglobulinemia, hematuria and mild elevation of urine protein-to-creatinine ratio, polyclonal peak in the gamma globulins, Leishmania spp. amastigotes in lymph nodes and bone marrow, and immunofluorescence antibody titer (IFAT) of 1:5120. The successful treatment included meglumine antimonate and allopurinol for 40 days, and metronidazole-spyramicin for 24 days. The dog was monitored up to 9 months and normalization of most hemato-biochemical abnormalities was achieved. The bone marrow qPCR for Leishmania infantum was negative, while IFAT was 1:160. Despite the systematic leishmaniosis prevention, the typical clinical disease can occur.

The study aim was to establish the prevalence of DEA 1, the most immunogenic and clinically important blood group in canine blood transfusion, in 7,414 dogs from Italy. The potential sensitization risk following a first transfusion and the acute reaction risk following a second transfusion given without a cross-matching and blood typing test were also calculated. Dogs tested were purebred (4,798) and mongrel (2,616); 38.8% were DEA 1 negative and 61.2% were DEA 1 positive. High prevalence for DEA 1 positive blood type was found in Ariegeois and English Setter, whereas German Shepherd and Boxer had higher DEA 1 negative blood type. Breeds with blood type never reported before included French Brittany Spaniel and Pug showing a high prevalence of DEA 1 positive type, while French Bulldog and West Highland White Terrier were more often DEA 1 negative. Just 48.8% of purebred and 13.9% of mongrel dogs were considered as prospective blood donors based upon their blood type. Most of the breeds had a sensitization risk of 20.0–25.0%. Rottweiler and Ariegeois had less risk of sensitization (9.4 and 4.2%) and the minor risk of an acute transfusional reaction (0.9–0.2%). The prevalence of DEA 1 positive and negative dogs in Italy agrees with most of the data already reported in the literature.